Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

U.S. trade policy has also heightened investor concerns over the potential impact to Novo Nordisk's key market. U.S. President Trump has threatened to unveil tariffs on pharmaceutical products in the ...

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...